Mechanisms of Insulin Facilitation of Memory
| Status: | Completed |
|---|---|
| Conditions: | Cognitive Studies, Endocrine |
| Therapuetic Areas: | Endocrinology, Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 21 - Any |
| Updated: | 11/8/2014 |
| Start Date: | July 2010 |
| End Date: | April 2014 |
| Contact: | Katayoon Karimi Goudarzi, MD, MA |
| Email: | neurolab.ut@gmail.com |
| Phone: | +1 (512) 471-7926 |
The study described in the present application will test the hypothesis that insulin
mediated facilitation of memory in Alzheimer's disease (AD) is achieved through enhanced
glutamatergic neurotransmission due to improvements in cerebral glucose metabolism. The
effect of a single dose of intranasal insulin on memory and cerebral glutamate
concentrations in adults with mild AD or amnestic mild cognitive impairment (aMCI), the
presumed prodromal phase of AD will be studied. Successful completion of this study may set
the stage for a larger-scale treatment trial of intranasal insulin for adults with memory
disorders. However, the use of insulin in this manner at this point in time is purely
experimental.
mediated facilitation of memory in Alzheimer's disease (AD) is achieved through enhanced
glutamatergic neurotransmission due to improvements in cerebral glucose metabolism. The
effect of a single dose of intranasal insulin on memory and cerebral glutamate
concentrations in adults with mild AD or amnestic mild cognitive impairment (aMCI), the
presumed prodromal phase of AD will be studied. Successful completion of this study may set
the stage for a larger-scale treatment trial of intranasal insulin for adults with memory
disorders. However, the use of insulin in this manner at this point in time is purely
experimental.
The specific aims of this project will be accomplished through a cross sectional repeated
measures design in which 15 participants with mild AD or amnestic MCI will undergo
assessments of brain structure and function 15 minutes after a single dose of insulin (20
IU) or placebo. Insulin and placebo conditions will be counterbalanced across participants.
Intranasal insulin or placebo administration: Saline and insulin (NovoLog) will be ordered
though the UT Student Health Services Pharmacy (Sharon Roberson, Chief Pharmacist) and
stored at 4°C, according to standard pharmacy protocols. Three ml doses of saline or insulin
will be packaged in nasal spray bottles (e.g., Spectrum Pharmacy Products bottles 969-17404P
and actuators 551-24362P) designed to deliver 100μL dose with each spray. A total volume of
200μL will be delivered during each administration (one 100μL dose in each nostril).
measures design in which 15 participants with mild AD or amnestic MCI will undergo
assessments of brain structure and function 15 minutes after a single dose of insulin (20
IU) or placebo. Insulin and placebo conditions will be counterbalanced across participants.
Intranasal insulin or placebo administration: Saline and insulin (NovoLog) will be ordered
though the UT Student Health Services Pharmacy (Sharon Roberson, Chief Pharmacist) and
stored at 4°C, according to standard pharmacy protocols. Three ml doses of saline or insulin
will be packaged in nasal spray bottles (e.g., Spectrum Pharmacy Products bottles 969-17404P
and actuators 551-24362P) designed to deliver 100μL dose with each spray. A total volume of
200μL will be delivered during each administration (one 100μL dose in each nostril).
Inclusion Criteria:
- Clinical diagnosis of probable AD
- Age over 21
- Clinical Dementia Rating of 0.5 or 1.0
- Mini Mental State Exam Score>15
Exclusion Criteria:
- preexisting diabetes
- significant neurological disease that might affect cognition, other than AD,
including stroke, Parkinson's disease, multiple sclerosis
- severe head injury with loss of consciousness > 30 minutes or with permanent
neurological sequelae
- significant medical illness or organ failure, such as uncontrolled hypertension or
cardiovascular disease, chronic obstructive pulmonary disease, liver disease, or
kidney disease
- current use of anti-psychotic or anti-convulsant medications
- current or previous use of hypoglycemic agents or insulin
- MRI contraindications
- claustrophobia
- pregnancy
We found this trial at
1
site
Click here to add this to my saved trials
